Detailed price information for Can-Fite Biopharma Ltd ADR (CANF-A) from The Globe and Mail including charting and trades.

Detailed price information for Can-Fite Biopharma Ltd ADR (CANF-A) from The Globe and Mail including charting and trades.

Can-Fite BioPharma (CANF) announced an update on its clinical development activities and financial status. Namodenoson drug candidate: Can-Fite is currently enrolling patients in a pivotal Phase III ...

During the conference, Can-Fite's management team will engage in one-on-one meetings with investors and potential partners to discuss the company’s business strategy, recent clinical milestones, and ...

RAMAT GAN, Israel, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs ...

RAMAT GAN, Israel, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs ...

The average one-year price target for Can-Fite BioPharma - Depositary Receipt (NYSEAM:CANF) has been revised to $4.84 / share. This is a decrease of 24.03% from the prior estimate of $6.38 dated ...

Can-Fite BioPharma's American depositary shares slid after its board of directors approved a 1-for-3,000 reverse share split. The ADSs were down 29% to 17 cents each in post-market trading on Tuesday.

Fintel reports that on December 17, 2025, D. Boral Capital maintained coverage of Can-Fite BioPharma - Depositary Receipt (NYSEAM:CANF) with a Buy recommendation. As of December 6, 2025, the average ...

Primary Safety Endpoint Demonstrated to Date; Top-Line Efficacy Data Expected in Q3 2026Ramat Gan, Israel, Jan. 20, 2026 ...